Davoceticept is under clinical development by Alpine Immune Sciences and currently in Phase I for Non-Small Cell Lung Cancer. According to GlobalData, Phase I drugs for Non-Small Cell Lung Cancer have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Davoceticept’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Davoceticept (ALPN-202) is under development for the treatment of colorectal cancer, lymphoma, solid tumor, pancreatic cancer, esophageal cancer, bile duct cancer (cholangiocarcinoma), kidney cancer (renal cell cancer), non-small cell lung cancer, merkel cell carcinoma, bladder carcinoma, nonmelanomatous skin cancer, head and neck cancer, neuroendocrine cancer, ovarian cancer, fallopian tube cancer, uterine cancer, uveal melanoma, adenoid cystic carcinoma , cervical cancer, melanoma, prostate cancer, thymoma (thymic epithelial tumor), cutaneous melanoma, Hodgkin lymphoma and non-Hodgkin lymphoma. It is administered through intravenous route. The drug candidate acts by targeting CTLA4, PD-1 and CD28. The drug candidate is developed based on soluble vIgD (variant immunoglobulin domain) platform technology. It is a fusion protein, synthesized by combining vIgDs with antibody Fc domains.
Alpine Immune Sciences overview
Alpine Immune Sciences (Alpine), formerly Nivalis Therapeutics Inc, is a pharmaceutical company that focuses on discovering and developing innovative, protein-based immunotherapies to treat cancer and autoimmune and inflammatory diseases. It provides ALPN-101 and ALPN-303 for the treatment of based immunotherapies and immune synapses to treat cancer and autoimmune and inflammatory diseases. Nivalis Therapeutics’ ALPN-101’s potential for the treatment of inflammatory diseases. The company offers a proprietary scientific platform that converts native immune system proteins into differentiated, multi-targeted therapeutics. Nivalis Therapeutics is headquartered in Seattle, Washington, the US.
For a complete picture of Davoceticept’s drug-specific PTSR and LoA scores, buy the report here.